Histidine, thiol- | 63798-18-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Histidine, thiol-
• 英文别名: (2S)-2-amino-3-(1H-imidazol-5-yl)propanethioic S-acid
• CAS: 63798-18-5
• 化学式: C₆H₉N₃OS
• 分子量: 171.22
• InChiKey: VSHRVZCUVVACJI-YFKPBYRVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  72.8
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Novel Glucagon Analogues
  申请人：NOVO NORDISK A/S

  公开号：US20160002311A1

  公开（公告）日：2016-01-07

  The present invention relates to novel peptide compounds which have a protracted profile of action and improved solubility and stability, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.

  本发明涉及新型肽化合物，其具有持续的作用特性、改善的溶解度和稳定性，以及这些化合物在治疗中的应用，包括将这些化合物用于治疗需要的患者的治疗方法，以及将这些化合物用于制造药物的应用。本发明的化合物在治疗高血糖、糖尿病和肥胖症以及与高血糖、糖尿病和肥胖症相关的各种疾病或病况方面具有特别的意义。
• NOVEL GLUCAGON ANALOGUES
  申请人：Novo Nordisk A/S

  公开号：EP2758426B1

  公开（公告）日：2019-08-07
• Acylated Glucagon Analogues
  申请人：Novo Nordisk A/S

  公开号：US20160271263A1

  公开（公告）日：2016-09-22

  The present invention relates to novel peptide compounds which have an improved physical stability in solution and improved solubility at neutral pH, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.
• 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO
  申请人：EMORY UNIVERSITY

  公开号：US20210308168A1

  公开（公告）日：2021-10-07

  Disclosed are halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can include tongaviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picornaviridae, Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infections.
• [EN] NOVEL GLUCAGON ANALOGUES<br/>[FR] NOUVEAUX ANALOGUES DU GLUCAGON
  申请人：NOVO NORDISK AS

  公开号：WO2011117416A1

  公开（公告）日：2011-09-29

  The present invention relates to novel peptide compounds which have an improved physical stability in solution and improved solubility at neutral pH, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.